Received 693 new patient start forms for FILSPARI ® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA ...
SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (TVTX) today reported its first quarter 2025 financial results and provided a corporate update. Net product sales for the first quarter of 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results